摘要
目的探讨低剂量右美托咪定(DEX)联合布托啡诺对瑞芬太尼引起的甲状腺手术患者术后痛觉过敏的影响。方法选择全身麻醉下拟行择期甲状腺手术的患者90例,采用随机数字表法分为生理盐水组(NR组)、右美托咪定组(DR组)及低剂量DEX联合布托啡诺组(DBR组),每组各30例。Von Frey细丝测定患者术后24h、48h的疼痛阈值,采用数字评定量表(NRS)对术后30min、2h、6h、12h、24h、48h患者的疼痛强度进行评估。结果DR组和DBR组患者术后24h、48h疼痛阈值显著高于NR组(P<0.05)。术后运动状态疼痛强度,DR组和DBR组患者术后NRS评分显著低于NR组(P<0.05),至少持续至术后12h。DR组低血压发作的患者数较高(10例,33.3%),而DBR组为2例(P<0.01)。结论低剂量DEX联合布托啡诺能够安全有效地减轻瑞芬太尼引起的甲状腺手术患者术后痛觉过敏。
Objective To assess the ffects of low-dose dexmedetomidine(DEX)combined with butorphanol collectively on remifentanil-induced postoperative hyperalgesia in patients undergoing thyroid surgery.Methods Ninety patients scheduled to undergo thyroid surgery were alotted into three groups randomly(n=30):Group NR(the saline group),Group DR(the dexmedetomidine group)and Group DBR(the Low-dose dexmedetomidine with butorphanol jointly group).The pain thresholds were measured by von Frey filaments at timepoint of 24h and 48h postoperatively.The pain intensity was evaluated at point of 30min,2h,6h,12h,24h and 48h postoperatively.Results The pain thresholds of Group DR and Group DBR were higher than that of Group NR(P<0.05).Postoperative pain intensity in mobilization of group DR and group DBR were lower than that of group NR(P<0.05),and the effect at least persists 12h after operation.While postoperative pain intensity at rest was similar among the three groups.The number of patients with hypotensive episodes in the DR group(10,33.3%)was higher than that in DBR group(2,6.7%).Conclusion Low-dose dexmedetomidine(DEX)combined with butorphanol is safe and effective in reducing remifentanil-induced postoperative hyperagesia in patients undergoing thyroid surgery.
出处
《浙江临床医学》
2020年第10期1513-1514,1516,共3页
Zhejiang Clinical Medical Journal
基金
中国中医科学院中央公益性研究基金项目(ZZ08080013)。
